Anti-KCJ12/ KCNJ12/ IRK-2 monoclonal antibody

Anti-KCJ12/ KCNJ12/ IRK-2 antibody for FACS & in-vivo assay

Target products collectionGo to KCNJ12/KCNJ12 products collection >>
(antibodies, antigen, VLP, mRNA, ORF viral vector, etc)

pdfMSDSpdfCOApdfDatasheet

Product information

Catalog No.Product NameSpecies Reactivity
GM-Tg-hg-MP0670-Ab-1/ GM-Tg-hg-MP0670-Ab-2Anti-Human KCNJ12 monoclonal antibodyHuman
GM-Tg-rg-MP0670-Ab-1/ GM-Tg-rg-MP0670-Ab-2Anti-Rat KCNJ12 monoclonal antibodyRat
GM-Tg-mg-MP0670-Ab-1/ GM-Tg-mg-MP0670-Ab-2Anti-Mouse KCNJ12 monoclonal antibodyMouse
GM-Tg-cynog-MP0670-Ab-1/ GM-Tg-cynog-MP0670-Ab-2Anti-Cynomolgus/ Rhesus macaque KCNJ12 monoclonal antibodyCynomolgus/ Rhesus macaque
GM-Tg-felg-MP0670-Ab-1/ GM-Tg-felg-MP0670-Ab-2Anti-Feline KCNJ12 monoclonal antibodyFeline
GM-Tg-cang-MP0670-Ab-1/ GM-Tg-cang-MP0670-Ab-2Anti-Canine KCNJ12 monoclonal antibodyCanine
GM-Tg-bovg-MP0670-Ab-1/ GM-Tg-bovg-MP0670-Ab-2Anti-Bovine KCNJ12 monoclonal antibodyBovine
GM-Tg-equg-MP0670-Ab-1/ GM-Tg-equg-MP0670-Ab-2Anti-Equine KCNJ12 monoclonal antibodyEquine

Size： 1mg | 10mg | 100mg



Product Description

Catalog No.GM-Tg-hg-MP0670-Ab-1/ GM-Tg-hg-MP0670-Ab-2; GM-Tg-rg-MP0670-Ab-1/ GM-Tg-rg-MP0670-Ab-2;
GM-Tg-mg-MP0670-Ab-1/ GM-Tg-mg-MP0670-Ab-2; GM-Tg-cynog-MP0670-Ab-1/ GM-Tg-cynog-MP0670-Ab-2;
GM-Tg-felg-MP0670-Ab-1/ GM-Tg-felg-MP0670-Ab-2; GM-Tg-cang-MP0670-Ab-1/ GM-Tg-cang-MP0670-Ab-2;
GM-Tg-bovg-MP0670-Ab-1/ GM-Tg-bovg-MP0670-Ab-2; GM-Tg-equg-MP0670-Ab-1/ GM-Tg-equg-MP0670-Ab-2
Products NameAnti-KCNJ12 monoclonal antibody
Formatmab
Target NameKCNJ12
Protein Sub-locationTransmembrane Protein
Category of antibodyFACS/Biofunctional Antibody
Derivation (species)Mouse
CH1+2+3 Isotype
(Receptor identification)		IgG
Type of Light Chain (VD-LC)N/A
Expression platformMammalian Expression
Bioactivity validationBinding affinity is validated by using flow cytometry with antigen overexpressed cell line. The biofunction of antibodies are validated in cell-based assay (IC50 or EC50 TBD).
TagFc
Products descriptionPre-made anti-KCNJ12 benchmark inhibitory monoclonal antibody(mab) (blocking antibody inhibitor) is expressed by mammalian cell line as a benchmark antibody for cell culture, FACS,ELISA or other affinity binding assay or functional assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic)
Purity Purity: ≥95% (SDS-PAGE)
Application Biological drug disovery including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Formulation & Reconstitution Lyophilized from GM's Protein Stability Buffer2 (PSB2,Confidential Ingredients) or PBS (pH7.4);
For PSB2, reconstituted with 0.9% sodium chloride;
For PBS, reconstituted with ddH2O.
Storage Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles.

Reference




    Data / case study


    Click to get more Data / Case study about the product.



    Associated products


    CategoryCat No.Products Name
    Target AntigenProducts DevelopingMulti-species KCJ12/ KCNJ12/ IRK-2 VLP (virus-like particle) (Products Developing)


    Target information

    Target IDGM-MP0670
    Target NameKCNJ12
    Gene ID3768,16515,117052,705326,403760,101082529,538479,100147042
    Gene Symbol and SynonymshIRK,hIRK1,hkir2.2x,IRK,IRK-2,IRK2,KCNJ12,kcnj12x,KCNJN1,Kir2.1,Kir2.2,MB-IRK2
    Uniprot AccessionQ14500,P52188,Q4TZY1
    Uniprot Entry NameKCJ12_HUMAN,KCJ12_RAT,KCJ12_BOVIN
    Protein Sub-locationTransmembrane Protein
    Category
    DiseaseN/A
    Gene EnsemblENSG00000184185
    Target ClassificationN/A

    The target: KCNJ12, gene name: KCNJ12, also named as IRK-2, IRK2, KCNJN1, Kir2.2, Kir2.2v, hIRK, hIRK1, hkir2.2x, kcnj12x. This gene encodes an inwardly rectifying K+ channel which may be blocked by divalent cations. This protein is thought to be one of multiple inwardly rectifying channels which contribute to the cardiac inward rectifier current (IK1). The gene is located within the Smith-Magenis syndrome region on chromosome 17. [provided by RefSeq, Jul 2008].



    About Gmab

    GDU
    GDU



    GMab, developed by GeneMedi, constitutes an advanced library of recombinant monoclonal antibodies, each meticulously designed to target specific molecular entities. Leveraging the sophisticated capabilities of GM’s Taurus™ and LIBRA™ platforms, GMab synthesizes antibodies characterized by high binding affinity, exceptional physicochemical stability, and optimal developability profiles.

    Through expression in mammalian cell lines, GMab has been established as a paradigmatic reference antibody. It holds significance in myriad domains of biological drug discovery, encompassing cellular cultivation, innovative assay methodologies, strategic animal model systematization, in-depth pharmacokinetic & pharmacodynamic (PK/PD) modeling, and intricate mechanism of action (MOA) investigations.